Consequently, clinical communication can shift from binary assertions (effective/ineffective, safe/unsafe) to a framework of probabilities + intervals + acceptance thresholds. For instance, the posterior probability of reaching a clinically meaningful weight-loss threshold can be presented alongside the posterior uncertainty of benefits in hard reproductive endpoints, rather than replacing the decision process with a single P -value
44 Semaglutide in Obese or Overweight Patients without Type 2 Diabetes Xie et al performed a systematic review of studies conducted in populations with OAO, but without T2DM, and indicated that semaglutide 2.4 mg had a significant advantage in decreasing body mass and HbA1c level, but the incidence of total AEs was also the highest and could cause hypoglycemia
Tirzepatides 5 mg, 10 mg, and 15 mg doses showed A1C reductions of 2.01, 2.24 and 2.30, respectively, surpassing semaglutides 1.86 reduction at the 1 mg dose
For diabetes treatment, NICE recommends continuing GLP-1 therapy only if HbA1c has fallen by at least 11 mmol/mol (1%) and weight has reduced by at least 3% after approximately 6 months, unless there are individual clinical reasons to continue